Pamidronate Disodium
**Pamidronate disodium** is a second-generation, nitrogen-containing bisphosphonate primarily utilized in veterinary medicine for the management of severe or refractory **hypercalcemia**, particularly hypercalcemia of malignancy (e.g., associated with lymphoma or apocrine gland anal sac adenocarcinoma) and vitamin D-analog toxicoses (e.g., cholecalciferol rodenticides, calcipotriene). Key clinical applications include: * **Hypercalcemia management**: Rapidly lowers dangerously high serum calcium levels when standard therapies (IV saline, furosemide, corticosteroids) are insufficient. * **Osteosarcoma and skeletal neoplasia**: Investigated as an adjuvant treatment to directly target micro-metastases and widely used as a palliative agent to reduce severe bone pain associated with osteolytic lesions. > **Clinical Pearl**: Because pamidronate is a potent inhibitor of bone resorption, its effects on serum calcium can be profound and long-lasting. It must be administered as a slow intravenous infusion (typically over 2 to 4 hours) diluted in calcium-free crystalloids to minimize the risk of acute nephrotoxicity.
Mechanism: Pamidronate is a nitrogen-containing bisphosphonate that strongly binds to **hydroxyapatite crystals** in the bone matrix, specifically targeting areas of active bone turnover. * **Inhibition of Bone Resorption**: Once internalized by osteoclasts during bone resorption, pamidronate inhibits the enzyme **farnesyl pyrophosphate synthase (FPPS)** in the mevalonate pathway. * **Osteoclast Apoptosis**: Inhibition of FPPS prevents the prenylation of small GTPase proteins (like **Ras** and **Rho**) → disruption of osteoclast cytoskeletal function and ruffled border formation → **induction of osteoclast apoptosis**. * **Antineoplastic Effects**: In vitro, it exhibits direct cytotoxic and cytostatic effects on human osteosarcoma cell lines, potentially exerting antiangiogenic effects and inhibiting tumor cell migration.
Dosing by species
- Control of hypercalcemia · 1.5-2 mg/kg IV over 4 hours · IV · From a retrospective study of 2 cats.
- Refractory hypercalcemia · 1 mg/kg IV given over 2 hours in 250 mL of normal saline · IV · every 4 weeks
- Control of hypercalcemia · 1.32 mg/kg in 150 mL of 0.9% saline with a 2 hour IV infusion · IV · can repeat in 1-3 weeks · Consider if parenteral saline, furosemide and corticosteroids do not resolve the issue.
- Treatment of cholecalciferol-induced toxicosis · 0.65-2 mg/kg in 0.9% NaCl · IV · on days 1 and 4 post-ingestion
- Attempting to reduce bone pain associated with osteosarcoma in combination with an NSAID · 1-2 mg/kg; diluted into 250 mL of 0.9% sodium chloride and administered as a CRI over 2 hours · IV · every 28 days
- Pain associated with skeletal neoplasias · 1-2 mg/kg IV over 2 hours · IV · every 21-28 days · Has been shown to provide pain relief in ~50% of dogs with skeletal neoplasia.
- Calcipotriene toxicosis · 1.3-2 mg/kg slow IV infusion · IV · single dose · In most cases, a single dose will lower calcium levels back to normal. Monitor calcium daily for at least 10 days after returning to normal.
- Control of hypercalcemia · 1.05-2 mg/kg IV over 4 hours · IV · From a retrospective study of 7 dogs.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Routes of administration
Contraindications
- Hypersensitivity to pamidronate or other bisphosphonates
- Severe renal impairment (use with extreme caution; not tested in humans with serum creatinine > 5 mg/dL)
Adverse effects
- Electrolyte abnormalities (hypomagnesemia, hypocalcemia, hypophosphatemia)
- Cardiac arrhythmias (secondary to electrolyte shifts)
- Renal toxicity (especially with rapid infusion)
- Transient bone pain
- Anemia
- Thrombocytopenia
- Granulocytosis
- Ophthalmic syndromes (e.g., scleritis - reported in humans)
Drug interactions
- Calcium-affecting drugs (e.g., furosemide, corticosteroids) · Can affect calcium levels; requires careful monitoring when used concurrently.
- Nephrotoxic drugs (e.g., cisplatin, aminoglycosides) · Potential for increased risk of nephrotoxicity; use with caution.
Monitoring
- Renal function (serum creatinine, BUN) and hydration status before treatment and prior to each dose
- Serum calcium (ionized preferred), phosphate, magnesium, and potassium
- CBC (baseline and continued if ongoing treatment)
- Urinalysis
Overdose
Overdosage of pamidronate may cause profound **hypocalcemia**, which can manifest clinically as muscle tremors, facial rubbing, seizures, or **tetany**. * **Treatment**: Should severe hypocalcemia occur, treat immediately with short-term, intravenous calcium supplementation (e.g., calcium gluconate) while monitoring the ECG.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.